OncRef

Clinical Trial: NCT02876302

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Dana-Farber Cancer Institute
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-07-24

Study Overview

Brief Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).

The Following drugs will be use in combination with Ruxolinitinib.

  • Paclitaxel (also called Taxol)
  • Doxorubicin also called Adriamycin
  • Cyclophosphamide, also called Cytoxan

Official Title

Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Conditions

Inflammatory Breast Cancer (IBC)

Intervention / Treatment

  • Drug: Ruxolitinib
  • Drug: Paclitaxel
  • Drug: Doxorubicin
  • Drug: Cyclophosphamide

Other Study ID Numbers

  • 16-151

Start Date (Actual)

2018-01-24

Primary Completion Date (Actual)

2022-12-31

Study Completion Date (Actual)

2024-10-01

Enrollment (Actual)

23

Study Type

Interventional

Phase

Phase 2